December 9, 2025 (Global) – Alcon has announced an amended merger agreement with STAAR Surgical, updating terms of its previously proposed acquisition to further strengthen the strategic alignment and streamline the transaction process. The amendment reflects ongoing discussions aimed at enhancing value for both companies and ensuring regulatory compliance. (Business Wire)
“The amended agreement underscores our commitment to completing the transaction efficiently while maximizing strategic benefits for our shareholders, customers, and patients,” said [Alcon Executive Name]. “STAAR Surgical’s advanced ophthalmic technologies complement Alcon’s portfolio and will help us better serve eye care professionals globally.”
STAAR Surgical is recognized for its innovative implantable lenses and refractive surgical solutions that address myopia, hyperopia, and presbyopia. The amended agreement is expected to accelerate integration planning, maintain continuity in innovation, and reinforce Alcon’s leadership in the ophthalmology and vision correction markets.
The companies emphasized that the amendment is intended to support a smooth transition and facilitate the completion of the merger, subject to customary closing conditions and regulatory approvals. Both Alcon and STAAR Surgical remain focused on patient care and the continued development of next-generation ophthalmic solutions.
Key Highlights of the Amended Merger Agreement
- Alcon announces amended merger agreement with STAAR Surgical
- Updates terms to streamline transaction and enhance strategic alignment
- Strengthens Alcon’s portfolio in implantable lenses and refractive surgery
- Aims to accelerate integration and maintain focus on innovation
- Pending customary closing conditions and regulatory approvals
Industry analysts view the amended agreement as a positive step toward completing the merger, which is expected to bolster Alcon’s position in the growing ophthalmology market and expand access to advanced vision correction technologies.
